Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 4/20 | 0.53 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | TARS1 | P26639 | 1/20 | 0.36 |
| ▸ | F9 | P00740 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1685321 | 0.91 | MAPKAPK5 (0.53) | MAPKAPK5TBK1MKNK1PRKCITARS1 | |
| SCHEMBL10134756 | 0.91 | MAPKAPK5 (0.53) | MAPKAPK5TBK1MKNK1PRKCITARS1 | |
| SCHEMBL1685196 | 0.89 | MAPKAPK5 (0.51) | MAPKAPK5TBK1MKNK1PRKCITARS1 | |
| SCHEMBL1685332 | 0.89 | MAPKAPK5 (0.51) | MAPKAPK5TBK1MKNK1PRKCITARS1 | |
| SCHEMBL1685156 | 0.89 | MAPKAPK5 (0.51) | MAPKAPK5TBK1MKNK1PRKCITARS1 | |
| SCHEMBL10133651 | 0.87 | MAPKAPK5 (0.51) | MAPKAPK5IKBKBCHUKCDK2 | |
| SCHEMBL1685135 | 0.86 | MAPKAPK5 (0.60) | MAPKAPK5TBK1IKBKBCHUKCDK2 | |
| SCHEMBL1685188 | 0.84 | MAPKAPK5 (0.53) | MAPKAPK5TBK1MKNK1PRKCIF9 | |
| SCHEMBL10133624 | 0.84 | MAPKAPK5 (0.66) | MAPKAPK5TBK1MKNK1PRKCIGSK3B | |
| SCHEMBL12618944 | 0.84 | MAPKAPK5 (0.53) | MAPKAPK5TBK1MKNK1PRKCIF9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | MAPKAPK5 19/4885TBK1 1968/4885MKNK1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.